Preliminary Results of the Open-Label Phase of a 2-Part Phase 1b Study That Evaluates Safety, Tolerability, Pharmacokinetics, and Efficacy of Investigational Microbiome Therapeutic SER-155 in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation (allo-HCT)

Doris M Ponce,Timothy Straub,Augustus Ge,Kelly Brady,Christopher B Ford,Zachariah Defilipp,Marcel R.M Van Den Brink,Bina Tejura,Mary-Jane Lombardo,Lisa Von Moltke,Emily Walsh,Gabrielle Glick,Jonathan U Peled,Nandita Khera,David Lyttle,Matthew D Puhl,Jennifer R Wortman,Matthew R Henn,David Lichter,Meghan Chafee,Satyajit Kosuri,Brooke R Hasson

doi:10.1016/j.jtct.2023.12.355

Preliminary Results of the Open-Label Phase of a 2-Part Phase 1b Study That Evaluates Safety, Tolerability, Pharmacokinetics, and Efficacy of Investigational Microbiome Therapeutic SER-155 in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation (allo-HCT)

Doris M Ponce, Timothy Straub + Show 20 more

https://doi.org/10.1016/j.jtct.2023.12.355

Copy DOI

Journal: Transplantation and Cellular Therapy

Publication Date: Feb 1, 2024

#Allogeneic Transplantation #Phase 1b Study + Show 6 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Preliminary Results of the Open-Label Phase of a 2-Part Phase 1b Study That Evaluates Safety, Tolerability, Pharmacokinetics, and Efficacy of Investigational Microbiome Therapeutic SER-155 in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation (allo-HCT)

Full Text